Categories

I-CARE Early Covid (3) I-CARE Flu and RSV (1) I-PREVENT (28) I-RECOVER Long Covid (3) I-RECOVER Post-Vaccine (3) MATH+ (20)

Tags

25-hydroxyvitamin D (2) 25‐HYDROXY VITAMIN D (2) Ambulatory treatment (2) Anti-inflammatory (2) Anti-Inflammatory Agents (1) Anticoagulant (2) Antimicrobial Cationic Peptides (1) Antiparasitic Agents (3) Antiviral (2) Ascorbic Acid (3) Calcifediol (1) Collagen (1) Coronavirus (2) COVID-19 (23) Dithiothreitol (1) Endothelial Barrier (1) Endothelial Permeability (1) Epidemiology (2) Ergocalciferols (1) Famotidine (7) Fixed drug eruption (1) Glucocorticosteroids (3) Heparanase (2) Human immunodeficiency virus (HIV) (1) Hydroxychloroquine (2) Inflammation (4) ivermectin (18) Melatonin (13) Methylprednisol (2) Nitric Oxide (1) Omicron (6) Onchocerciasis (1) pharmacokinetics (1) Pneumonia (2) SARS-CoV-2 (20) Sars-CoV2 (2) Sepsis (3) Septic (2) Spike Protein (5) Stevens–Johnson syndrome (SJS) (1) Tempol (1) viral infection (3) Vitamin C (3) Vitamin D (6) vitamin D 2 (1)

  • Reference: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

    Published On: December 23, 2021

    The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation.

    Categories:

    Tags: ACE2 protein, SARS-CoV-2, Spike Protein